Indivior (NASDAQ:INDV) Reaches New 12-Month High – Here’s What Happened

Indivior PLC (NASDAQ:INDV) reached a new 52-week high during trading on Wednesday . The stock traded as high as $40.27 and last traded at $40.1940, with a volume of 715931 shares trading hands. The stock had previously closed at $39.59.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 16th. Northland Securities set a $50.00 target price on shares of Indivior in a report on Tuesday, January 20th. HC Wainwright increased their target price on shares of Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Finally, Weiss Ratings lowered shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $39.33.

Indivior Stock Performance

The business’s fifty day simple moving average is $32.24 and its 200-day simple moving average is $32.85. The firm has a market capitalization of $4.82 billion, a PE ratio of 20.26 and a beta of 0.90.

Indivior (NASDAQ:INDV) last posted its earnings results on Tuesday, March 31st. The company reported $0.96 EPS for the quarter. The company had revenue of $317.00 million for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%. Sell-side analysts expect that Indivior PLC will post 3.35 earnings per share for the current fiscal year.

Insider Activity at Indivior

In other news, Director Stuart A. Kingsley bought 940 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The shares were bought at an average cost of $31.86 per share, for a total transaction of $29,948.40. Following the completion of the transaction, the director owned 5,582 shares of the company’s stock, valued at approximately $177,842.52. This represents a 20.25% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 0.74% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Oaktree Capital Management LP grew its holdings in shares of Indivior by 2,241.6% in the third quarter. Oaktree Capital Management LP now owns 257,785,398 shares of the company’s stock valued at $6,215,206,000 after purchasing an additional 246,776,273 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Indivior by 18.4% in the first quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock valued at $79,757,000 after purchasing an additional 1,299,425 shares in the last quarter. Fuller & Thaler Asset Management Inc. grew its holdings in shares of Indivior by 101.0% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 6,371,534 shares of the company’s stock valued at $228,611,000 after purchasing an additional 3,201,639 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Indivior by 57.9% in the fourth quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company’s stock valued at $196,403,000 after purchasing an additional 2,008,078 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of Indivior by 65.5% in the fourth quarter. State Street Corp now owns 4,659,281 shares of the company’s stock valued at $167,175,000 after purchasing an additional 1,844,532 shares in the last quarter. 60.33% of the stock is owned by hedge funds and other institutional investors.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.